Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Buy
71
ZYME Quote, Financials, Valuation and Earnings
Last price:
$26.96
Seasonality move
:
-1.76%
Day range:
$25.94 - $27.68
52-week range:
$9.03 - $28.49
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.09x
P/B ratio:
6.31x
Volume:
756.8K
Avg. volume:
1.5M
1-year change:
87.61%
Market cap:
$2B
Revenue:
$76.3M
EPS (TTM):
-$0.85
Analysts' Opinion
-
Consensus RatingZymeworks, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.54, Zymeworks, Inc. has an estimated upside of 32.66% from its current price of $26.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 100% downside risk from its current price of $26.79.
Fair Value
-
According to the consensus of 12 analysts, Zymeworks, Inc. has 32.66% upside to fair value with a price target of $35.54 per share.
ZYME vs. S&P 500
-
Over the past 5 trading days, Zymeworks, Inc. has overperformed the S&P 500 by 1.61% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Zymeworks, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zymeworks, Inc. has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Zymeworks, Inc. reported revenues of $27.6M.
Earnings Growth
-
Zymeworks, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Zymeworks, Inc. reported earnings per share of -$0.26.
Enterprise value:
1.8B
EV / Invested capital:
5.27x
Price / LTM sales:
15.09x
EV / EBIT:
--
EV / Revenue:
13.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-27.72x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$121.7M
Return On Assets:
-14.54%
Net Income Margin (TTM):
-47.16%
Return On Equity:
-18.82%
Return On Invested Capital:
-17.82%
Operating Margin:
-80.07%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $461.6M | $62.2M | $134.5M | $16M | $27.6M | |
| Gross Profit | $445.3M | $51.3M | $121.7M | $13.3M | $25M | |
| Operating Income | $204.8M | -$121M | -$70.6M | -$34.2M | -$22.1M | |
| EBITDA | $221M | -$110.2M | -$57.8M | -$31.5M | -$19.5M | |
| Diluted EPS | $3.12 | -$1.51 | -$0.85 | -$0.39 | -$0.26 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $336.8M | $190.7M | $374.6M | $343.8M | $291.7M | |
| Total Assets | $420.4M | $300.3M | $556.4M | $487.2M | $397.3M | |
| Current Liabilities | $75.4M | $57.7M | $72.8M | $83.9M | $42M | |
| Total Liabilities | $141.4M | $120.5M | $132M | $120.2M | $77.2M | |
| Total Equity | $278.9M | $179.8M | $424.3M | $367M | $320.1M | |
| Total Debt | $28.9M | $25.5M | $22.5M | $17.3M | $15.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $185.4M | -$52.7M | -$62.5M | -$6.1M | -$31.9M | |
| Cash From Investing | -$227.2M | $46.2M | $14.7M | $71.9M | $310K | |
| Cash From Financing | $28.5M | $38M | -$8.1M | -$14.9M | -$2.5M | |
| Free Cash Flow | $182.5M | -$57.1M | -$64.5M | -$7.1M | -$32.3M | |
ZYME
Sector
Market Cap
$2B
$28.1M
Price % of 52-Week High
94.03%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
0.64%
-1.49%
1-Year Price Total Return
87.61%
-17.13%
Beta (5-Year)
1.269
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$26.37
200-day SMA
Buy
Level
$15.52
Bollinger Bands (100)
Buy
Level
14.18 - 23.22
Chaikin Money Flow
Buy
Level
1.2M
20-day SMA
Buy
Level
$26.24
Relative Strength Index (RSI14)
Buy
Level
61.41
ADX Line
Buy
Level
9.52
Williams %R
Neutral
Level
-36.5079
50-day SMA
Buy
Level
$22.18
MACD (12, 26)
Buy
Level
6.64
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
412.8K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2231)
Buy
CA Score
(Annual)
Level (-0.2048)
Sell
Beneish M-Score
(Annual)
Level (-1.202)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.0386)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Stock Forecast FAQ
In the current month, ZYME has received 12 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ZYME average analyst price target in the past 3 months is $35.54.
-
Where Will Zymeworks, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zymeworks, Inc. share price will rise to $35.54 per share over the next 12 months.
-
What Do Analysts Say About Zymeworks, Inc.?
Analysts are divided on their view about Zymeworks, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zymeworks, Inc. is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Zymeworks, Inc.'s Price Target?
The price target for Zymeworks, Inc. over the next 1-year time period is forecast to be $35.54 according to 12 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ZYME A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zymeworks, Inc. is a Buy. 12 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ZYME?
You can purchase shares of Zymeworks, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zymeworks, Inc. shares.
-
What Is The Zymeworks, Inc. Share Price Today?
Zymeworks, Inc. was last trading at $26.96 per share. This represents the most recent stock quote for Zymeworks, Inc.. Yesterday, Zymeworks, Inc. closed at $26.79 per share.
-
How To Buy Zymeworks, Inc. Stock Online?
In order to purchase Zymeworks, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ZYME Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ZYME
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
6.31x
1.81x
Price / LTM sales
15.09x
1.59x
Growth Metrics
ZYME
Sector
Revenue growth
72.59%
4.62%
Earnings growth
34.02%
11.06%
Revenue (5-year growth)
20.9%
6.5%
Earnings forecast
-$0.32
-$0.21
Profitability
ZYME
Sector
Profitability FY 2024
$65.1M
$3.6M
Return on invested capital
-17.82%
-31.84%
Return on assets
-14.54%
-27.96%
Return on equity
-18.82%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
11
Estimated Next Earnings Date
Feb
5
Balance Sheet
ZYME
Sector
Total cash
$251.9M
$26.4M
Short term investments
$159.7M
$25.7M
Total assets
$463.1M
$76.9M
Long term debt
$15.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 3.18% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 1.39% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
